Satellos Bioscience Inc. (NASDAQ:MSLE) Receives $19.75 Consensus Price Target from Brokerages

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have earned an average rating of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $19.75.

A number of analysts have recently weighed in on MSLE shares. Wells Fargo & Company set a $18.00 price target on shares of Satellos Bioscience in a report on Thursday, July 9th. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Guggenheim started coverage on shares of Satellos Bioscience in a report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price target on the stock. HC Wainwright increased their price objective on Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Monday, May 11th.

Satellos Bioscience Stock Up 2.0%

Shares of NASDAQ MSLE opened at $8.52 on Wednesday. Satellos Bioscience has a 1-year low of $4.64 and a 1-year high of $13.39. The stock’s fifty day moving average is $7.15. The stock has a market cap of $177.56 million, a PE ratio of -5.32 and a beta of 1.53.

Satellos Bioscience (NASDAQ:MSLE) last posted its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). Analysts predict that Satellos Bioscience will post -1.69 EPS for the current year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.